OREGA Biotech
Created in 2010
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
1,527Activities
Technologies
Entity types
Location
15 Chem. du Saquin, 69130 Écully, France
Écully
France
Employees
Scale: 2-10
Estimated: 8
SIREN
520831819Engaged corporates
0
0 0Added in Motherbase
3 years, 8 months ago
biotech Value proposition
Discovery of novel immune checkpoint inhibitors for cancer immunotherapy
OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. The company was incepted in 2010 and is managed by Jeremy Bastid, CEO and Gilles Alberici, President.
The science at OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our in vivo screening approach aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Our lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate (2016) Pharma and then partnered with AstraZeneca (2018). It is currently in phase 2 clinical trial in NSCLC.
The second program, at preclinical stage, targets a new regulator of the immune response in order to overcome resistance to anti-PD1 antibodies.
The investors are initiative Octalfa, SHAM Innovation Santé, Rhône-Alpes Création and INSERM-Transfert Initiative.
Monoclonal Antibody, Biotechnology, immuno-oncology, and immunotherapyOriginal language
Discovery of novel immune checkpoint inhibitors for cancer immunotherapy
OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. The company was incepted in 2010 and is managed by Jeremy Bastid, CEO and Gilles Alberici, President.
The science at OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our in vivo screening approach aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Our lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate (2016) Pharma and then partnered with AstraZeneca (2018). It is currently in phase 2 clinical trial in NSCLC.
The second program, at preclinical stage, targets a new regulator of the immune response in order to overcome resistance to anti-PD1 antibodies.
The investors are initiative Octalfa, SHAM Innovation Santé, Rhône-Alpes Création and INSERM-Transfert Initiative.
Orega Biotech
Development of innovative immunotherpeutics for cancer
https://www.orega-biotech.com/
